Your session is about to expire
← Back to Search
Intra-arterial Drug Therapy for Cerebral Vasospasm (iVAST Trial)
iVAST Trial Summary
This trial is studying how well different combinations of drugs work in restoring the blood flow in the arteries of the brain after a subarachnoid hemorrhage. The different combinations of drugs will be compared to each other and to the standard treatment to see which works best.
iVAST Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowiVAST Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.iVAST Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have received drug treatment through an artery in all 3 arterial territories.My angiogram showed more than 50% narrowing after aneurysm treatment.I am 18-80 years old and had a brain aneurysm rupture, with complications within 3-21 days after surgery.I have symptoms of narrowed blood vessels in my brain.I am younger than 18 or older than 80.My condition is a severe brain hemorrhage.
- Group 1: Verapamil
- Group 2: Nicardipine
- Group 3: Nicardipine + Verapamil + Nitroglycerin
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what capacity is this clinical trial reaching its enrollment quota?
"Affirmative, the clinical trial is actively searching for patients. It was posted on August 29th 2016 and last updated on December 15 2021; it requires 330 participants from 3 medical centres."
Are persons of a younger age bracket allowed to partake in this clinical research?
"Applicants who meet the criteria of this medical study must be between 18 and 80 years old. For those below 18, there are 2 clinical trials available; for senior citizens over 65, 25 studies have been launched."
Would I be eligible for enrollment in this experiment?
"This research project is engaging 330 participants, aged between 18 and 80, who suffer from cerebral vasospasm. The prerequisite qualifications for involvement in the study include being an adult patient of age 18-80 years old with a ruptured aneurysm(s) experiencing symptomatic vasospasm (clinical or TCD), as well as having developed said condition within 3 to 21 days post operatively."
Are there any previous investigations that have explored Nicardipine use?
"Nicardipine was initially studied in 2009 at Seoul National University Bundang Hospital. Since then, 157 clinical trials have been conducted and 15 are currently underway - the majority of them being based out of Manhasset, New york."
For what medical concerns is Nicardipine typically prescribed?
"Nicardipine is a common medication used to manage the symptoms of angina pectoris. This drug can also provide relief for those suffering from atrial fibrillation, flutter and unstable angina pectoris."
Are there opportunities for individuals to be part of this experiment?
"This clinical trial is actively on the lookout for participants. It was first posted in August of 2016 and most recently revised at the end of December 2021, according to information available from clinicaltrials.gov."
Has Nicardipine been granted regulatory authorization by the FDA?
"Nicardipine is categorized as safe by our team at Power, since it has reached Phase 4 of clinical trials and therefore been given approval. This safety rating was assigned a score of 3."
Share this study with friends
Copy Link
Messenger